ArticleCancer imaging : the official publication of the International Cancer Imaging Society2025
Correlations between Ki67 expression and uptake of
Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to evaluate the correlation between Ki67 expression and uptake values of 68Ga-FAPI-04 and 18F-FDG PET/CT in different types of tumor lesions.
methodsPatients who underwent concurrent 68Ga-FAPI-04 and 18F-FDG PET/CT and were candidates for biopsy of any lesion positive on either imaging agent were enrolled in this retrospective study. Receiver operating characteristic (ROC) curve analysis was conducted on Ki67 prediction of 18F-FDG and 68Ga-FAPI-04 positive lesions. The maximum standard uptake values (SUVmax) and tumor-to-background ratio (TBR) of the lesions were collected. The mean SUVmax and mean TBR of lesions from different tumor groups were compared using the Kruskal-Wallis test. Spearman rho test was used to analyze the correlation between the same parameters of two types of PET. The protein expression of Ki67 was examined by immunohistochemical staining. The correlation between the parameters of two imaging agents and Ki67 expression in tissue samples was analyzed by Spearman’s rho test.
resultsA total of 66 patients were included (31 men, 35 women; mean age 56.11 ± 12.64 years), with 69 malignant tumor samples analyzed. All tumors exhibited Ki67 expression, with varying intensity and positivity rates ranging from 1% to 95%. ROC curve analysis showed that Ki67 expression had a good ability to predict visual positive of 18F-FDG (AUC = 0.819, p < 0.0001), but it did not have statistical significance in predicting positive of 68Ga-FAPI-04 (AUC = 0.698, p = 0.069). The optimal critical value for Ki67 was 15%. Overall, 18F-FDG SUVmax and TBR were moderately positively correlated with Ki67 (rho = 0.471, p < 0.0001 and rho = 0.405, P < 0.001, respectively), while the 68Ga-FAPI-04 parameters showed no significant correlation with Ki67 (rho = 0.121, p = 0.321 and rho = 0.119, P = 0.329, respectively). In subgroup analysis, the correlation between 18F-FDG (SUVmax and TBR) and Ki67 remained moderate in lesions with Ki67 > 15% (rho = 0.346, p = 0.008 and rho = 0.327, p = 0.013, respectively). 18F-FDG (SUVmax and TBR) and Ki67 also showed a particularly correlation in tumor groups of hematology and head and neck tumors. In any tumor group or Ki67 subgroup, there was no significant association between 68Ga-FAPI-04 (SUVmax and TBR) and Ki67. Regarding the correlation between two imaging agents, the tracer correlation in Ki67≤15% lesions is stronger than that in Ki67 > 15% lesions. Unlike 18F-FDG, which showed no difference between tumor groups (SUVmax: p = 0.260, TBR: p = 0.072), significant heterogeneity in 68Ga-FAPI-04 uptake was observed between different tumor groups (SUVmax: p = 0.002, TBR: p = 0.004).
conclusionMechanistic differences likely exist between 68Ga-FAPI-04 and Ki67. In contrast, 18F-FDG may serve as a direct indicator for assessing tumor proliferative capacity. Limitations of this study could be addressed in future research with larger sample sizes and subgroup analyses to yield more valuable insights.
trial registrationChiCTR, ChiCTR2100044131. Registered 10 October 2022, https://www.chictr.org.cn , ChiCTR2100044131.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.